Emiliano Giangreco
Overview
Explore the profile of Emiliano Giangreco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
85
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macaluso F, Renna S, Fries W, Viola A, Cappello M, Salerno I, et al.
Inflamm Bowel Dis
. 2024 Oct;
PMID: 39460746
No abstract available.
2.
Macaluso F, DAntonio E, Fries W, Viola A, Ksissa O, Cappello M, et al.
Dig Liver Dis
. 2023 Sep;
56(1):15-20.
PMID: 37741749
Background: Real-world evidence is needed to determine the value of tofacitinib (TOFA) for the treatment of ulcerative colitis (UC). Aim: To assess the safety and effectiveness of TOFA in clinical...
3.
Macaluso F, Grova M, Mocciaro F, Di Mitri R, Privitera A, Distefano M, et al.
J Gastroenterol Hepatol
. 2023 May;
38(9):1503-1509.
PMID: 37148148
Background And Aim: Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) in this setting is poorly known....
4.
Macaluso F, Grova M, Saladino M, Cappello M, Demarzo M, Privitera A, et al.
Dig Liver Dis
. 2022 Sep;
55(4):471-477.
PMID: 36127230
Background: The effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) in patients with Crohn's disease (CD) as third-line biologic therapies is unclear. Aims: We performed a multicentre, real-world assessment of the...
5.
Macaluso F, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, et al.
Inflamm Bowel Dis
. 2022 Apr;
29(2):217-221.
PMID: 35385102
Background: Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD) are not at higher risk of being infected by...
6.
Macaluso F, Cappello M, Crispino F, Grova M, Privitera A, Piccillo G, et al.
Dig Liver Dis
. 2021 Dec;
54(5):629-634.
PMID: 34924320
Background: The role of Vedolizumab (VDZ) as therapeutic option for the postoperative recurrence of Crohn's disease (CD) following ileocolonic resection is unknown. Aims: To assess the effectiveness of VDZ in...
7.
Macaluso F, Cappello M, Busacca A, Fries W, Viola A, Costantino G, et al.
J Gastroenterol Hepatol
. 2021 Jun;
36(11):3041-3049.
PMID: 34152636
Background And Aim: There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease. We aimed to perform a multicenter, observational, prospective study on safety and effectiveness of...
8.
Macaluso F, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, et al.
United European Gastroenterol J
. 2020 Aug;
8(9):1045-1055.
PMID: 32772830
Background: Biologically naïve patients with inflammatory bowel disease treated with vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre, observational cohort study was performed on the effectiveness and safety...
9.
Macaluso F, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, et al.
J Gastroenterol Hepatol
. 2020 May;
36(1):105-111.
PMID: 32428981
Background And Aim: There are no head-to-head randomized controlled trials between biologics in Crohn's disease (CD). We aimed to perform a multicenter, real-life comparison of the effectiveness of vedolizumab (VDZ)...
10.
Macaluso F, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, et al.
Inflamm Bowel Dis
. 2020 Feb;
27(2):182-189.
PMID: 32083291
Background: No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. Methods: The Sicilian Prospective Observational Study of Patients With IBD Treated With...